Radient Technologies Inc V.RTI.H

RE:GW Pharma assigned patent

[lscfa]

US version....

https://patents.google.com/patent/US7344736B2/en

lscfa wrote:

Seems very similar to Canopy assigned patent and is patented in many countries but not US. Maybe this is why GW is manufacturing its CBD drug outside the US and why Canopy is arguing that importing the drug into the US is a patent infringement.   
 

Abstract
A method for extracting cannabinoids from plant material comprising a decarboxylation step, extraction with liquid carbon dioxide (CO ₂ ) and a step of reducing the content of non-interest materials into the extract, characterized in that the extraction with liquid CO ₂ at subcritical conditions at a temperature in the range of 5 to 15 ° C and a pressure in the range of 50 to 70 bar, and wherein the step of reducing the content of non-interest materials in the extract is a precipitation with a C1-C5 alcohol, wherein the material to be treated is heated to a temperature above room temperature prior to the addition of the C1-C5 alcohol.

https://patents.google.com/patent/DE10337458B4/en?oq=DE10337458B4

 

Canopy complaint:

For example, on information and belief, GW, with knowledge that the active pharmaceutical ingredient in Epidiolex, CBD, is made outside the United States by a process patented by the ’632 Patent, has actively induced and continues to induce third parties (e.g., physicians and/or pharmacies) and end users (e.g., patients) to offer for sale, sell, and/or use Epidiolex in the United States in violation of 35 U.S.C. § 271(g). On information and belief, GW, acting alone and/or through intermediaries, markets Epidiolex throughout the United States through a commercial organization consisting of sales, medical affairs, marketing, and market access/payer teams.